MedTrace Logo

Accessory Pathway Antegrade Effective Refractory Period Among WPW Patients: the Risk in Relation to the Location

NCT04106622 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2020-01-30

No results posted yet for this study

Summary

To correlate the antegrade effective refractory period of the accessory pathway with its anatomical location in the heart.

To investigate whether the accessory pathway location can predict the high risk nature of the accessory pathway

Conditions

  • Wolff-Parkinson-White Syndrome

Interventions

PROCEDURE

electrophysiological study

To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways: The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study.. The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval during spontaneous or induced AF.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • M K Ibrahim, Msc · Assiut University

  • S S Atta, Professor · Assiut University

  • S M Taha, Lecturer · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2022-03-01
Completion
2023-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04106622 on ClinicalTrials.gov